Esomeprazole magnesium salt

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种质子泵抑制剂，通过抑制壁细胞中的 H+/K+-ATP 酶来减少胃酸分泌。

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells; the (S)-(?)-enantiomer of omeprazole for treatment of dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease.Ulcer Approved.

Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.Cell Viability Assay Cell Line:MDA-MB-468 cells Concentration:25 μM, 50 μM, 75 μM, 100 μM Incubation Time:20 hours Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.Cell Viability Assay Cell Line:MDA-MB-468 cells Concentration:25 μM, 50 μM, 75 μM, 100 μM Incubation Time:20 hours Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

——

Membrane Transporter/Ion Channel

Proton Pump

Proton Pump

Other Indications

Ulcer

1198768-91-0

368.7126

C17H18MgN3O3S+

>98% (HPLC)

10 mM in DMSO

CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC.[Mg]

1H-Benzimidazole, 6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, magnesium salt (1:1)

(-20℃)

With Ice Pack

≥ 2 years